Navigation Links
Campbell Alliance Hires Joe Dillon, Expands Business Development Practice
Date:3/9/2009

RALEIGH, N.C., March 9 /PRNewswire/ -- Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced that Joe Dillon has joined its Business Development Practice. Mr. Dillon will work closely with the Business Development Practice to help pharmaceutical and biotech clients address business challenges and develop comprehensive strategies related to in- and out-licensing, opportunity assessment, and overall business development strategy.

Mr. Dillon has more than twenty years of experience in the pharmaceutical industry. Most recently, he was the Senior Vice President and Head of Corporate Development and Valuations at the Mattson Jack Group. In this role, Mr. Dillon was responsible for designing and developing valuation, risk assessment, and deal structuring systems, as well as improving the business development partnering process. He has also been a regular speaker at many pharmaceutical-related conferences throughout the US and Europe.

"Joe has extensive expertise in business development strategy and knowledge of commercializing products. This combination of skills, coupled with his long-standing industry experience, will be a valuable asset to our firm and to the pharmaceutical and biotech clients that depend on our services," said John Campbell, CEO of Campbell Alliance.

Prior to his role at Mattson Jack, Mr. Dillon was Principal at Dillon Technologies, an executive consulting firm based in Tampa, FL. In this role, he provided management and financial consulting services to firms in challenging situations. Providing interim executive management, he served as President and CEO of Pharmaceutical Development Center, a pharmaceutical manufacturer and development company. Mr. Dillon has also held leadership positions with Oread, Inc., a pharmaceutical manufacturer and development company, and with Hoechst Marion Roussel, a multi-billion dollar pharmaceutical company and predecessor company of Sanofi-Aventis.

Mr. Dillon graduated with a BA in Business Administration with honors from Washburn University and an MBA from Kansas State University.

About the Business Development Practice at Campbell Alliance

The Business Development Practice at Campbell Alliance helps pharmaceutical licensing executives achieve an edge over the competition. Our consultants provide experienced counsel to clients who need assistance developing BD strategies, identifying partners, prioritizing targets, evaluating opportunities, and negotiating deals.

The firm's team includes seasoned consultants and industry professionals in pharmaceutical and biotech BD who have identified, assessed, and executed numerous in-licensing deals. They have also been valuable in aiding out-licensors, helping clients improve internal processes for pharmaceutical business development, and assisting top executives in charting new strategies in corporate development.

About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include most of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Managed Markets, Sales, and Trade and Distribution. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and London, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.

    CONTACT:
    James Forte
    Director, Public and Media Relations
    Campbell Alliance
    919-844-7100, extension 7195
    jforte@campbellalliance.com


'/>"/>
SOURCE Campbell Alliance
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
2. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
3. Campbell Alliance Named Best Place to Work by Triangle Business Journal
4. Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver
5. Campbell Alliance Launches New Practice Area Focused on Trade and Distribution
6. Campbell Alliance Trade and Distribution Practice to Chair CBI 3rd Annual Fee for Service and EDI Data Management Conference
7. Campbell Alliance Brand Management Practice to Discuss Managing Launch Logistics at the EyeForPharma Oncology Summit
8. Campbell Alliance Brand Management and Managed Markets Practices to Speak at CBIs Early Commercialization Conference
9. Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference
10. Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies
11. Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
Breaking Biology Technology:
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):